• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Cassava Sciences Inc (NQ: SAVA )

    28.22 +2.08 (+7.96%)
    Streaming Delayed Price Updated: 11:51 AM EST, Nov 15, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Cassava Sciences Inc

    < Previous 1 2
    ...
    7 8 9 10 11 12 13 14 15
    ...
    33 34 Next >
    $100 Invested In Cassava Sciences 20 Years Ago Would Be Worth This Much Today
    Via Benzinga
    Why Is Cassava Sciences (SAVA) Stock Up Today?
    Today's big move in Cassava Sciences and SAVA stock has many investors watching this company's trials closer than ever. 
    Via InvestorPlace
    12 Health Care Stocks Moving In Monday's Intraday Session
    Gainers 
    Via Benzinga
    CASSAVA SCIENCES INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Cassava Sciences, Inc. - SAVA
    From Kahn Swick & Foti, LLC
    Via Business Wire
    Is the Stock Market Open on Election Day 2022?
    Investors are wondering if the stock market is open on Election Day this year as they seek out extra time to head to the polls! 
    Via InvestorPlace
    Cassava Sciences: Q3 Earnings Insights
    Cassava Sciences (NASDAQ:SAVA) reported its Q3 earnings results on Monday, November 7, 2022 at 09:00 AM. Here's what investors need to know about the announcement. 
    Via Benzinga
    Cassava Sciences Has a Big Warning for SAVA Stock Short Sellers
    SAVA stock is in the green after reporting earnings. The company also filed a lawsuit against short sellers, alleging misleading statements. 
    Via InvestorPlace
    Cassava Sciences Reports Third Quarter Financial Results for 2022 and Business Updates
    From Cassava Sciences, Inc.
    Via GlobeNewswire
    What the Latest Controversy Really Means for SAVA Stock
    SAVA stock continues to be dogged by controversy, but the risk/reward proposition for this biotech largely remains the same. 
    Via InvestorPlace
    Cassava Sciences Files Lawsuit Against Perpetrators of “Short and Distort” Campaign
    From Cassava Sciences, Inc.
    Via GlobeNewswire
    Why Is Cassava Sciences (SAVA) Stock Down 10% Today?
    SAVA stock is in the red after a piece from Probes Reporter accused Cassava of being involved with two undisclosed SEC investigations. 
    Via InvestorPlace
    A New Study Makes Cassava Sciences Stock an Interesting Buy
    With the biotech firm moving forward with an open-label study of its Alzheimer's treatment simufilam, SAVA stock is one to watch. 
    Via InvestorPlace
    Cassava Sciences Announces Expansion of Leadership Team
    From Cassava Sciences, Inc.
    Via GlobeNewswire
    10 Health Care Stocks Whale Activity In Today's Session
    This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
    Via Benzinga
    Short Interest Sector Focus: Healthcare Sector
    As of the close of business on Wednesday, 10/19, we captured the Top 10 Highest Short Interest % stocks within the Healthcare Sector. The average short interest for stocks within the Healthcare sector... 
    Via Benzinga
    Alzheimer’s Pipeline of New Treatments Race to Improve Quality of Life for Patients
    Palm Beach, FL – October 20, 2022 – FinancialNewsMedia.com News Commentary – Last year, about 6.2 million people aged 65 and above living in America were suffering from Alzheimer’s disease, (AD) which... 
    Via FinancialNewsMedia
    CASSAVA SCIENCES INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Cassava Sciences, Inc. - SAVA
    From Kahn Swick & Foti, LLC
    Via Business Wire
    SAVA Stock Alert: Cassava Sciences Extends Trial
    SAVA stock is in focus after Cassava announced that it would begin an open-label study of its investigational Alzheimer's drug, simufilam. 
    Via InvestorPlace
    Cassava Sciences Announces Initiation of an Open-label Extension Study
    From Cassava Sciences, Inc.
    Via GlobeNewswire
    Don’t Let Misconduct Allegations Cloud Your Perception of SAVA Stock
    It's easy to get mired in the controversy surrounding Cassava Sciences, but distracted SAVA stock traders might miss an opportunity. 
    Via InvestorPlace
    3 Alzheimer Stocks to Buy as the Race for a Cure Heats Up
    Here is a look at three names that buy-and-hold investors may want to consider as the race to find a cure for Alzheimer's disease accelerates 
    Via MarketBeat
    Exposures Product Safety
    2 Signals to Watch Before Buying SAVA Stock
    SAVA stock got ahead of itself in September, but if it continues to pull back, a solid entry point could emerge for this risky biotech play. 
    Via InvestorPlace
    EXCLUSIVE: Top 10 Stocks Searched On Benzinga Pro In September: Where Do Tesla, Apple, Bed Bath & Beyond Rank?
    Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for traders to see the latest news on the overall market and individual tickers. 
    Via Benzinga
    Why Revelation Biosciences Shares Are Trading Higher By 29%, Here Are 50 Stocks Moving In Thursday's Mid-Day Session
    Gainers Statera Biopharma, Inc. (NASDAQ: STAB) rose 98% to $0.2777. Statera Biopharma was recently granted European patent number EP3206708 titled "Methods And Compositions For The Treatment Of... 
    Via Benzinga
    $100 Invested In Cassava Sciences 15 Years Ago Would Be Worth This Much Today
    Cassava Sciences (NASDAQ:SAVA) has outperformed the market over the past 15 years by 3.29% on an annualized basis producing an average annual return of 9.08%. Currently, Cassava Sciences has a market... 
    Via Benzinga
    $1000 Invested In This Stock 20 Years Ago Would Be Worth $10,000 Today
    Cassava Sciences (NASDAQ:SAVA) has outperformed the market over the past 20 years by 4.23% on an annualized basis producing an average annual return of 12.02%. Currently, Cassava Sciences has a market... 
    Via Benzinga
    How High Can SAVA Stock Go Once the Controversy Clears?
    If a reproduced SEC letter concerning Cassava Sciences' clearance is legit, SAVA stock could head much higher. 
    Via InvestorPlace
    'Right Now, You've Still Got To Avoid The Stock,' Jim Cramer Says About This Aerospace Company
    On CNBC’s "Mad Money Lightning Round," Jim Cramer said Sherwin-Williams Co (NYSE: SHW) might go lower as the PE (price-to-earnings) multiple is still "way too high" on the stock. 
    Via Benzinga
    These Stocks Are On The Radar After Biogen-Eisai's Surprising Alzheimer's Trial Win
    Via Benzinga
    Why Is Acumen (ABOS) Stock Up 95% Today?
    Acumen Pharmaceuticals (ABOS) stock is rocketing higher on Wednesday but it's not due to any recent news from the company. 
    Via InvestorPlace
    < Previous 1 2
    ...
    7 8 9 10 11 12 13 14 15
    ...
    33 34 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.